Mabwell (Shanghai) Bioscience Past Earnings Performance
Past criteria checks 0/6
Mabwell (Shanghai) Bioscience's earnings have been declining at an average annual rate of -8.1%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 57.4% per year.
Key information
-8.1%
Earnings growth rate
-3.4%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 57.4% |
| Return on equity | -56.6% |
| Net Margin | -634.1% |
| Next Earnings Update | 29 Nov 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Mabwell (Shanghai) Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 169 | -1,074 | 389 | 823 |
| 30 Jun 24 | 153 | -1,085 | 412 | 817 |
| 31 Mar 24 | 191 | -1,018 | 388 | 841 |
| 31 Dec 23 | 128 | -1,053 | 368 | 836 |
| 30 Sep 23 | 107 | -936 | 366 | 718 |
| 30 Jun 23 | 107 | -945 | 318 | 783 |
| 31 Mar 23 | 28 | -976 | 275 | 779 |
| 31 Dec 22 | 28 | -955 | 268 | 759 |
| 30 Sep 22 | 26 | -947 | 268 | 754 |
| 30 Jun 22 | 20 | -853 | 233 | 676 |
| 31 Mar 22 | 20 | -833 | 227 | 651 |
| 31 Dec 21 | 16 | -770 | 189 | 623 |
| 30 Sep 21 | 11 | -699 | 158 | 560 |
| 31 Dec 20 | 5 | -643 | 86 | 581 |
| 31 Dec 19 | 29 | -928 | 590 | 356 |
| 31 Dec 18 | 37 | -225 | 38 | 164 |
Quality Earnings: 688062 is currently unprofitable.
Growing Profit Margin: 688062 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688062 is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.
Accelerating Growth: Unable to compare 688062's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688062 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Return on Equity
High ROE: 688062 has a negative Return on Equity (-56.6%), as it is currently unprofitable.